Fennec Pharmaceuticals
FENC
105 hedge funds and large institutions have $175M invested in Fennec Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 44 increasing their positions, 18 reducing their positions, and 8 closing their positions.
213% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 8
144% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 18
76% more capital invested
Capital invested by funds: $99.6M → $175M (+$75.4M)
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
17% more funds holding
Funds holding: 90 → 105 (+15)
0.39% less ownership
Funds ownership: 47.15% → 46.76% (-0.39%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$4.12M |
| 2 |
PCA
Prospect Capital Advisors
Sausalito,
California
|
+$4.06M |
| 3 |
AIC
AWM Investment Company
New York
|
+$3.59M |
| 4 |
BlackRock
New York
|
+$2.93M |
| 5 |
RA
Rosalind Advisors
Toronto,
Ontario, Canada
|
+$2.28M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCA
Southpoint Capital Advisors
New York
|
-$16.9M |
| 2 |
SCM
Solas Capital Management
Darien,
Connecticut
|
-$4.84M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$674K |
| 4 |
GJL
Gendell Jeffrey L
|
-$511K |
| 5 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
-$472K |
FENC Hedge Fund Activity: Q2 2026 in Review
105 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Fennec Pharmaceuticals (FENC) for Q2 2026, worth a combined $175M — up 76% from $99.6M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new FENC positions and 8 closed out — a net gain of 17 holders — while 44 added to existing stakes and 18 trimmed.
The largest buyer was AIGH Capital Management, adding an estimated $4.12M. The largest seller was Southpoint Capital Advisors, exiting entirely with an estimated $16.9M sold.
- 105 institutional investors held Fennec Pharmaceuticals (FENC) as of Q2 2026, up from 90 in Q1 2026.
- Funds reported $175M of Fennec Pharmaceuticals stock for Q2 2026, up 76% quarter-over-quarter.
- 25 funds opened new Fennec Pharmaceuticals positions in Q2 2026 and 8 closed out, a net change of +17 holders.
- The largest Fennec Pharmaceuticals buyer in Q2 2026 was AIGH Capital Management, an estimated $4.12M added.
- The largest Fennec Pharmaceuticals seller in Q2 2026 was Southpoint Capital Advisors, an estimated $16.9M sold.
Based on aggregated 13F filings for Q2 2026.